Value of Preoperative Inflammatory Burden Index in Predicting Overall Survival and Progression in Nonmetastatic Muscle-Invasive Bladder Cancer.

IF 0.9 4区医学 Q4 UROLOGY & NEPHROLOGY

Archivos Espanoles De Urologia Pub Date : 2025-07-01 DOI:10.56434/j.arch.esp.urol.20257806.89

Rıdvan Kayar, Kemal Kayar, Emre Tokuç, Ramazan Topaktaş, Muhammet Çiçek, Samet Demir, Metin Öztürk

{"title":"Value of Preoperative Inflammatory Burden Index in Predicting Overall Survival and Progression in Nonmetastatic Muscle-Invasive Bladder Cancer.","authors":"Rıdvan Kayar, Kemal Kayar, Emre Tokuç, Ramazan Topaktaş, Muhammet Çiçek, Samet Demir, Metin Öztürk","doi":"10.56434/j.arch.esp.urol.20257806.89","DOIUrl":null,"url":null,"abstract":"Purpose: This study evaluates the prognostic significance of the inflammatory burden index (IBI) and related systemic inflammatory markers, namely, C-reactive protein-to-albumin ratio (CAR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), and pan-immune inflammation value (PIV), in predicting survival outcomes in patients with nonmetastatic muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC).Methods: A total of 115 patients treated between January 2014 and January 2023 were included. IBI, CAR, SII, PLR, MLR, SIRI, NLR, and PIV were calculated. Kaplan-Meier, Cox regression, and receiver operating characteristic (ROC) curve analyses were performed to determine the impact of these biomarkers on overall survival (OS) and progression-free survival (PFS).Results: ROC analysis for OS prediction revealed the highest predictive accuracy for PIV (area under curve (AUC) = 0.784, p < 0.001), followed by SIRI (AUC = 0.751) and IBI (AUC = 0.747). For PFS prediction, IBI demonstrated the strongest predictive value (AUC = 0.672, p = 0.002), followed by CAR (AUC = 0.663, p = 0.003) and PIV (AUC = 0.662, p = 0.003). Multivariate Cox regression analysis identified PIV (hazard ratio (HR) = 3.673, p < 0.001), SIRI (HR = 3.074, p < 0.001), and IBI (HR = 2.209, p = 0.002) as independent predictors of OS. High IBIs were significantly associated with advanced tumor stage (T stage) (p = 0.025), lymphovascular invasion (p = 0.002), and perineural invasion (p = 0.023) but not with lymph node metastasis (p = 0.713).Conclusions: IBI and associated hematological markers are valuable for predicting survival outcomes in patients with MIBC. The findings support the integration of these biomarkers with other prognostic tools to enhance the accuracy of treatment outcome predictions.","PeriodicalId":48852,"journal":{"name":"Archivos Espanoles De Urologia","volume":"78 6","pages":"660-670"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos Espanoles De Urologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.56434/j.arch.esp.urol.20257806.89","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study evaluates the prognostic significance of the inflammatory burden index (IBI) and related systemic inflammatory markers, namely, C-reactive protein-to-albumin ratio (CAR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), and pan-immune inflammation value (PIV), in predicting survival outcomes in patients with nonmetastatic muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC).

Methods: A total of 115 patients treated between January 2014 and January 2023 were included. IBI, CAR, SII, PLR, MLR, SIRI, NLR, and PIV were calculated. Kaplan-Meier, Cox regression, and receiver operating characteristic (ROC) curve analyses were performed to determine the impact of these biomarkers on overall survival (OS) and progression-free survival (PFS).

Results: ROC analysis for OS prediction revealed the highest predictive accuracy for PIV (area under curve (AUC) = 0.784, p < 0.001), followed by SIRI (AUC = 0.751) and IBI (AUC = 0.747). For PFS prediction, IBI demonstrated the strongest predictive value (AUC = 0.672, p = 0.002), followed by CAR (AUC = 0.663, p = 0.003) and PIV (AUC = 0.662, p = 0.003). Multivariate Cox regression analysis identified PIV (hazard ratio (HR) = 3.673, p < 0.001), SIRI (HR = 3.074, p < 0.001), and IBI (HR = 2.209, p = 0.002) as independent predictors of OS. High IBIs were significantly associated with advanced tumor stage (T stage) (p = 0.025), lymphovascular invasion (p = 0.002), and perineural invasion (p = 0.023) but not with lymph node metastasis (p = 0.713).

Conclusions: IBI and associated hematological markers are valuable for predicting survival outcomes in patients with MIBC. The findings support the integration of these biomarkers with other prognostic tools to enhance the accuracy of treatment outcome predictions.

查看原文本刊更多论文

术前炎症负担指数在预测非转移性肌浸润性膀胱癌总体生存和进展中的价值。

目的:本研究评估炎症负担指数（IBI）及相关全身炎症指标，即c反应蛋白与白蛋白比值（CAR）、全身免疫炎症指数（SII）、血小板与淋巴细胞比值（PLR）、单核细胞与淋巴细胞比值（MLR）、全身炎症反应指数（SIRI）、中性粒细胞与淋巴细胞比值（NLR）、泛免疫炎症值（PIV）的预后意义。预测接受根治性膀胱切除术（RC）的非转移性肌肉浸润性膀胱癌（MIBC）患者的生存结果。方法：选取2014年1月至2023年1月收治的115例患者。计算IBI、CAR、SII、PLR、MLR、SIRI、NLR、PIV。通过Kaplan-Meier、Cox回归和受试者工作特征（ROC）曲线分析来确定这些生物标志物对总生存期（OS）和无进展生存期（PFS）的影响。结果：预测OS的ROC分析显示，PIV的预测准确率最高（曲线下面积(AUC) = 0.784, p < 0.001），其次是SIRI （AUC = 0.751）和IBI （AUC = 0.747）。对于PFS的预测，IBI表现出最强的预测值（AUC = 0.672, p = 0.002），其次是CAR （AUC = 0.663, p = 0.003）和PIV （AUC = 0.662, p = 0.003）。多因素Cox回归分析发现PIV（风险比(HR) = 3.673, p < 0.001）、SIRI （HR = 3.074, p < 0.001）和IBI （HR = 2.209, p = 0.002）是OS的独立预测因子。高ibi与肿瘤晚期（T期）（p = 0.025）、淋巴血管侵袭（p = 0.002）和神经周围侵袭（p = 0.023）显著相关，但与淋巴结转移无关（p = 0.713）。结论：IBI和相关血液学指标对于预测MIBC患者的生存结果是有价值的。研究结果支持这些生物标志物与其他预后工具的整合，以提高治疗结果预测的准确性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archivos Espanoles De Urologia UROLOGY & NEPHROLOGY-

CiteScore

0.90

自引率

0.00%

发文量

111

期刊介绍： Archivos Españoles de Urología published since 1944, is an international peer review, susbscription Journal on Urology with original and review articles on different subjets in Urology: oncology, endourology, laparoscopic, andrology, lithiasis, pediatrics , urodynamics,... Case Report are also admitted.